Intralesional interferon alpha-2b in the treatment of basal cell carcinoma and squamous cell carcinoma: revisited.

Abstract

Intralesional interferon (IFN) alpha-2b has been shown to be a safe and effective mode of treatment for basal cell carcinoma and squamous cell carcinoma. Multiple studies published in the 1980s through the early 1990s have demonstrated the efficacy of intralesional interferon in the treatment of these malignancies. Unfortunately, this modality appears to be underused. This article serves to remind dermatologists that in addition to cryotherapy, electrodesiccation, and surgical excision, intralesional IFN-alpha is an important part of the armamentarium in the treatment of nonmelanoma skin cancers. In addition to a review of the literature, we present eight cases in seven patients successfully treated with intralesional IFN for basal cell carcinoma and squamous cell carcinoma. Its nonsurgical approach and excellent cosmetic results make IFNalpha-2b an attractive option for patients and an important alternative when other treatment modalities are impractical or contraindicated.